Diseño sin título (5)

Crepes Sin categoría @en

Biosearch complete product stability studies of the probiotic strain Lactobacillus coryniformis CECT5711 K8

In February, Biosearch successfully completed the final product stability studies of a probiotic strain (Lactobacillus coryniformis CECT5711 K8), which in several human trials it has been shown to be significantly effective in reducing respiratory infections of viral origin in a population older than 65 years.
Lactobacillus coryniformis strain, CECT5711 K8, has shown in various works an effective enhancing power of the immune response. These works include two clinical trials in humans in vaccination protocols against the hepatitis A and influenza viruses. The effect was especially powerful in the senior population, the population most susceptible to infections and in which vaccination against influenza is recommended due to the higher rate of complications it causes in this population. Taking Lactobacillus K8 not only improved the response to the influenza vaccine in this population, it also showed that the attenuated / killed virus in the vaccines was better recognized by the immune system, increasing the response. The effectiveness of probiotic treatment was further demonstrated by reducing the incidence of local symptoms related to respiratory infections such as cough, nasal congestion and sore throat by 48.3%. In fact, pain reliever consumption in these older adults was reduced by up to 86%.
Although there is no evidence of the effect of probiotics on infection with the new coronavirus, the fact that Lactobacillus K8 has been shown to improve immunological defenses against viruses as different as those of hepatitis or influenza, shows its potential to improve the immune response in general, being able to be an ally in situations of greater vulnerability to viral infections.